

RPMI 2650 | 300323

Description

Organism

Tissue

Disease

Metastatic site

Synonyms RPMI-2650, RPMI2650, 2650

Age 52

Gender

Ethnicity

Morphology

Growth properties

Citation RPMI 2650(300323)

Biosafety level 1

NCBI_TaxID 9606

CellosaurusAccession CVCL_1664

Isoenzymes G6PD, B

RPMI 2650 | 300323

Reverse transcriptase

Products

Culture Medium

EMEM(MEM), w: 2mM L- , w: 2.2g/L NaHCO3, w: EBSS(820100a)

Supplements

10% FBS 1% NEAA

Dissociation Reagent

Doubling time

48

Subculturing

PBS . T25 3~5ml, T75 5~10ml PBS . T25

Split ratio

1:2 1:4

Fluid renewal

2

Post-Thaw Recovery

24 48

Freeze medium

(FBS) + 10% DMSO , CM-1(Cytion 800100)

RPMI 2650 | 300323

Thawing and Culturing Cells

1. .
2. -150°C , 3 .
3. 37°C 40~60 .
4. , 70% .
5. 8ml 15ml .
6. 300 x g 3 .
7. 10ml . T25 , T25
8. .

Incubation Atmosphere

37°C, 5% CO₂ .

Flask Coating

Freezing Procedure

-78°C .

Shipping Conditions

-78°C .

Storage Conditions

-150°C -196°C .80°C .

/ / HLA

Sterility

PCR .

RPMI 2650 | 300323

STR

- Amelogenin:** x,x
- CSF1PO:** 9,11
- D13S317:** 11, 12
- D16S539:** 11, 12
- D5S818:** 12, 13
- D7S820:** 8,11
- TH01:** 6,8
- TPOX:** 8
- vWA:** 16, 18
- D3S1358:** 17
- D21S11:** 28,33.2
- D18S51:** 16
- Penta E:** 11 19
- Penta D:** 9.1
- D8S1179:** 9,13
- FGA:** 23,25

HLA

- A*:** '02:01:01, '03:01:01
- B*:** '07:02:01, '35:01:01
- C*:** '03:03:01, '07:02:01
- DRB1*:** '07:01:01, '08:01:01G
- DQA1*:** '02:01:01, '04:01:01
- DQB1*:** '03:03:02, '04:02:01
- DPB1*:** '04:01:01
- E:** '01:01:01, '01:03